Background and purpose: Bone changes are secondary to chronic anemia, hypertrophy, enlargement of skull and also due to therapeutic agents such as desferal. Ât present in developed counties there is reduction of bone deformity as a result of proper treatment and management of the disease. The present study has been conducted in order to evaluate the type and severity of bone changes in thalas...

Beta Thalassemia major patients receive repeated transfusions in order to compensate anemia and use desferal to remove iron overload. Comparing immunoglobulins and complement components in the serum of these patients with normal range shows a significant increase (P<0.001) in IgG, IgA and IgM and a decrease in C3c and C4. The regression analysis confirms a relation between the numbers of transf...

Background: Deferoxamine mesylate is still the conventional and well-known iron chelator for patients with thalassemia major. However, due to some marketing issues the well-known original brand, Desferal®, produced by Novartis Pharmaceuticals Company is not as available as before. The generic brands of Deferoxamine have been introduced in many parts of the world including Iran; however, they ar...